Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Conditions
Interventions
CAP-1002
Placebo
Locations
9
United States
University of California, Davis
Sacramento, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Nemours Children's Hospital
Orlando, Florida, United States
University of Iowa
Iowa City, Iowa, United States
University of Massachusetts Medical Center
Worcester, Massachusetts, United States
Washington University
St Louis, Missouri, United States
Start Date
April 4, 2018
Primary Completion Date
March 10, 2020
Completion Date
March 10, 2020
Last Updated
May 28, 2025
NCT01568658
NCT05724173
NCT06094205
NCT07138963
NCT07129954
NCT03698149
Lead Sponsor
Capricor Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions